LCTC Lifeloc Technologies (LCTC) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001493137
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about LCTC
Insiders, 180 days
+$3.5K net bought
2 buyers
Lifeloc Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Lifeloc Technologies, Inc insiders bought a net $3.5K of stock across 14 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 19, 2023.
- +35.1% median (+35.4% mean) 90-day return after 3 previous buys.
- The trade is 3.1% of the 41,625 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: CEO and President Willkomm Wayne bought about $3.2K of LCTC on Jun 23, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 23, 2024.
- The trade is 9.1% of the 1,100 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Director Kornelsen Michael bought about $250 of LCTC on Jun 16, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Kashenberg Adam W. bought about $3.8K of LCTC on Feb 28, 2025; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
Insider activity: Controller Heim Michelle sold about $5.7K of LCTC on Feb 28, 2025, the largest insider sale at the company on our record.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 23, 2024.
- The trade is 0.6% of the 2,100,119 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Chief Financial Officer KORNELSEN VERN D bought about $46.5K of LCTC on Feb 28, 2025; 2 other insiders bought within 30 days.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$3.5K over 180 days
more than 65% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+5.7% year over year
below 63% of Medical Devices
Margin
-27.4% net margin
below 57% of Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LCTC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LCTC: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in LCTC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LCTC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Wayne R. Willkomm, Ph.D.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$302.5K
$302.5K
$110.8K
+12%
n/a
2024
$296.8K
$296.8K
$109.1K
+28%
n/a
2023
$286.1K
$286.1K
$92.3K
+3%
n/a
2022
$270.6K
$270.6K
$78.5K
+0%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $3.5K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
LCTC financials
Revenue growth
+5.7%
XBRL, annual
Net margin
-27.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LCTC
| FY Dec 2025 | $9.0M |
| FY Dec 2024 | $8.5M |
| FY Dec 2023 | $9.3M |
| FY Dec 2022 | $8.5M |
| FY Dec 2021 | $7.1M |
| Jun 2026 | $2.4M |
| Mar 2026 | $2.3M |
| Dec 2025 | $2.3M |
| Sep 2025 | $2.3M |
| Jun 2025 | $2.2M |
| Mar 2025 | $2.3M |
| Dec 2024 | $1.9M |
| Sep 2024 | $2.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-22.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LCTC
| FY Dec 2025 | -27.4% |
| FY Dec 2024 | -12.3% |
| FY Dec 2023 | +2.2% |
| FY Dec 2022 | -5.4% |
| FY Dec 2021 | +9.6% |
| Jun 2026 | -5.5% |
| Mar 2026 | -6.7% |
| Dec 2025 | -66.9% |
| Sep 2025 | -11.7% |
| Jun 2025 | -17.7% |
| Mar 2025 | -12.9% |
| Dec 2024 | -16.4% |
| Sep 2024 | -7.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$835.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LCTC
| FY Dec 2025 | -$962.1K |
| FY Dec 2024 | -$1.9M |
| FY Dec 2023 | -$532.6K |
| FY Dec 2022 | -$158.9K |
| FY Dec 2021 | -$82.9K |
| Jun 2026 | -$133.2K |
| Mar 2026 | -$134.7K |
| Dec 2025 | -$344.2K |
| Sep 2025 | -$222.9K |
| Jun 2025 | -$294.7K |
| Mar 2025 | -$100.4K |
| Dec 2024 | -$353.9K |
| Sep 2024 | -$527.3K |
At each fiscal year end
Single quarter
Debt to equity
0.28x
long-term 2026-06-30 plus current 2025-09-30 (9 months older than the period end); equity 2026-06-30
Debt to equity LCTC
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | 0.19x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | 0.20x |
| Jun 2026 | 0.28x |
| Mar 2026 | 0.28x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.20x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.18x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.34x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-09-30 (9 months older than the period end)
Cash flow to debt LCTC
| FY Dec 2025 | -0.45x |
| FY Dec 2024 | -1.13x |
| FY Dec 2023 | -0.43x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 0.14x |
| Jun 2026 | -0.34x |
| Mar 2026 | -0.48x |
| Dec 2025 | -0.45x |
| Sep 2025 | -0.77x |
| Jun 2025 | -0.87x |
| Mar 2025 | -0.68x |
| Dec 2024 | -1.13x |
| Sep 2024 | -1.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-42.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LCTC
| FY Dec 2025 | -47.8% |
| FY Dec 2024 | -16.7% |
| FY Dec 2023 | +3.3% |
| FY Dec 2022 | -7.1% |
| FY Dec 2021 | +10.8% |
| Jun 2026 | -42.7% |
| Mar 2026 | -45.5% |
| Dec 2025 | -47.8% |
| Sep 2025 | -21.0% |
| Jun 2025 | -19.8% |
| Mar 2025 | -17.2% |
| Dec 2024 | -16.7% |
| Sep 2024 | -10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-26.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LCTC
| FY Dec 2025 | -32.1% |
| FY Dec 2024 | -12.1% |
| FY Dec 2023 | +2.4% |
| FY Dec 2022 | -5.2% |
| FY Dec 2021 | +7.7% |
| Jun 2026 | -26.4% |
| Mar 2026 | -29.2% |
| Dec 2025 | -32.1% |
| Sep 2025 | -15.2% |
| Jun 2025 | -13.9% |
| Mar 2025 | -12.1% |
| Dec 2024 | -12.1% |
| Sep 2024 | -7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LCTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LCTC
| FY Dec 2025 | -17.8% |
| FY Dec 2024 | -18.1% |
| FY Dec 2023 | -2.6% |
| FY Dec 2022 | -8.5% |
| FY Dec 2021 | -3.6% |
| Jun 2026 | -11.8% |
| Mar 2026 | -15.7% |
| Dec 2025 | -17.8% |
| Sep 2025 | -17.6% |
| Jun 2025 | -17.7% |
| Mar 2025 | -17.1% |
| Dec 2024 | -18.1% |
| Sep 2024 | -15.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LCTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 31.57x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 16.29x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.5M
market value at close 2026-10-23 on 2026-08-01 shares, plus long-term 2026-06-30 plus current 2025-09-30 (9 months older than the period end), minus cash 2022-06-30
Enterprise value LCTC
| FY Dec 2025 | $5.5M |
| FY Dec 2024 | $6.2M |
| FY Dec 2023 | $4.4M |
| FY Dec 2022 | $4.3M |
| FY Dec 2021 | $9.9M |
| Jun 2026 | $7.0M |
| Mar 2026 | $3.9M |
| Dec 2025 | $5.5M |
| Sep 2025 | $7.5M |
| Jun 2025 | $7.3M |
| Mar 2025 | $8.1M |
| Dec 2024 | $6.2M |
| Sep 2024 | $10.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-8.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield LCTC
| FY Dec 2025 | -14.6% |
| FY Dec 2024 | -25.5% |
| FY Dec 2023 | -9.8% |
| FY Dec 2022 | -3.0% |
| FY Dec 2021 | -0.7% |
| Jun 2026 | -10.2% |
| Mar 2026 | -19.6% |
| Dec 2025 | -14.6% |
| Sep 2025 | -11.3% |
| Jun 2025 | -15.2% |
| Mar 2025 | -13.7% |
| Dec 2024 | -25.5% |
| Sep 2024 | -16.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LCTC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.0M | $8.5M | $9.3M | $8.5M |
| Gross profit | $3.6M | $3.4M | $4.0M | $3.1M |
| Operating income | -$1.2M | -$1.4M | -$191.1K | -$650.3K |
| Net income | -$2.5M | -$1.1M | $205.6K | -$455.8K |
| EPS (diluted) | -0.90 | -0.41 | 0.08 | -0.19 |
| Operating cash flow | -$499.3K | -$1.3M | -$525.7K | $54.3K |
| Long-term debt | $1.1M | $1.1M | $1.2M | $1.2M |
SEC XBRL, fiscal years, as known on 2026-10-27
LCTC Stock Sonar score 5/7 axes
Find similar shapesCompareLCTC ranks highest on risk and compliance (80th percentile) and insider conviction (69th), and lowest on growth (37th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LCTC filings, in plain words
Are Lifeloc Technologies insiders buying or selling LCTC?
In the 180 days to 2026-10-27, Lifeloc Technologies insiders were net buyers, a net $3.5K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-27, Lifeloc Technologies insiders were net buyers of LCTC, a net $3.5K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
